Camryn Davis
Family · Gloversville, NYNPI 1518693746
Payments from drug & device makers
Across 63 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$172
- AbbVie$114
- Novo Nordisk$95
- Otsuka America Pharmaceutical, Inc.$85
- Xeris Pharmaceuticals, Inc.$62
- Lundbeck LLC$54
- plus $498 from 17 others
What the payments were for
- Food & beverage$1,081100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $172 |
| AbbVie | 6 | $114 |
| Novo Nordisk | 6 | $95 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Xeris Pharmaceuticals, Inc. | 4 | $62 |
| Lundbeck LLC | 3 | $54 |
| GSK | 3 | $52 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| AstraZeneca | 3 | $48 |
| Kyowa Kirin, Inc. | 2 | $46 |
| EMD Serono, Inc. | 2 | $40 |
| Bayer | 2 | $38 |
| Exact Sciences | 2 | $30 |
| Exeltis, USA Inc. | 2 | $26 |
| UCB, Inc. | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Vertex | 1 | $19 |
| Biogen | 1 | $18 |
| SK Life Science, Inc. | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$1,081 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Terconazole | 13 | $354 |
Paid to pharmacies, not to this prescriber.
Other family in Gloversville
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.